New hope for transplant patients with devastating lung damage
NCT ID NCT02669251
Summary
This early-stage study is testing an oral drug called alvelestat for people who develop a serious lung scarring condition (BOS) after a stem cell transplant. The goal is to find a safe dose that blocks a harmful enzyme thought to cause the lung damage and to see if that dose can help stabilize or improve lung function. The study is for adults who have this specific transplant complication and have already tried standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.